Th17 cells are major players in multiple autoimmune diseases and are developmentally contingent on reciprocal functionality between the transcription factor Retineic acid receptor-related orphan nuclear receptor gamma (RORγt) and Forkhead box protein P3 (Foxp3). Here we deciphered a previously unappreciated role of Steroid receptor coactivator 1 (SRC1) in defining the lineage decision for the development of Th17 versus induced T-regulatory (iTreg) cells. We demonstrate that SRC1 functions as a critical coactivator for RORγt in vivo to promote the functional dominance of RORγt over Foxp3 and thus establishing an unopposed Th17 differentiation program. In the absence of SRC1, T cell polarization resulted in decreased IL-17 + and increased Foxp3
Th17 cells are major players in multiple autoimmune diseases and are developmentally contingent on reciprocal functionality between the transcription factor Retineic acid receptor-related orphan nuclear receptor gamma (RORγt) and Forkhead box protein P3 (Foxp3). Here we deciphered a previously unappreciated role of Steroid receptor coactivator 1 (SRC1) in defining the lineage decision for the development of Th17 versus induced T-regulatory (iTreg) cells. We demonstrate that SRC1 functions as a critical coactivator for RORγt in vivo to promote the functional dominance of RORγt over Foxp3 and thus establishing an unopposed Th17 differentiation program. In the absence of SRC1, T cell polarization resulted in decreased IL-17 + and increased Foxp3
+ cells during both in vitro differentiation and in vivo development of experimental autoimmune encephalomyelitis. Mechanistically, T cell receptor (TCR) signaling molecule protein kinase C theta (PKC-θ)-mediated phosphorylation of SRC1 is important for inducing enhanced RORγt-SRC1 interaction, stable DNA binding, and resultant IL-17A transcription. Furthermore, phospho-SRC1-mediated recruitment of CARM1 induced prominent asymmetric dimethylation of H3R17 while preventing repressive H3K9 trimethylation and hence further modifying the IL-17 locus for optimal transcription. Moreover, binding of phospho-SRC1 to RORγt displaced bound Foxp3, leading to prompt degradation of the dissociated Foxp3 via a ubiquitin-proteosomal pathway and hence reversing the inhibitory action of Foxp3 on RORγt activity. Thus, SRC1 acts as a crucial molecular mediator to integrate positive PKC-θ-dependent TCR signals to induce peak RORγt activity and establish phenotypic dominance of Th17 over the iTreg pathway.
T cell differentiation | Th17 | Treg | EAE I nflammatory Th17 cells and inhibitory Treg cells, which can be differentiated from the same pool of naive T cells (1, 2) , determine the magnitude of immune responses. Skewing the balance toward Th17 cells could lead to aggravating autoimmunity, whereas tipping the balance toward Tregs induces tolerance (3) . Generation of a robust Th17 response is essential for clearing pathogens and requires the differentiation and expansion of Th17 cells while reciprocally inhibiting the formation of Tregs. On the other hand, effective prevention of Th17-mediated autoimmunity requires the repression of Th17 while reciprocally promoting the formation of Treg cells. Th17 differentiation is directed by the master transcriptional factor RORγt, whereas Treg differentiation is instructed by the transcriptional repressor Foxp3. The initial differentiation phase of Th17 is marked by coexpressed RORγt and Foxp3 (4, 5) . Foxp3 can bind directly to RORγt protein and antagonize its ability to bind DNA, thus exerting a negative effect on RORγt transcriptional activity (6, 7) . However, it remains unclear exactly how RORγt can overcome Foxp3-mediated inhibition to promote the development of IL-17 + cells. The steroid receptor coactivator (SRC) family consists of three members, SRC1, SRC2, and SRC3. SRCs are important cofactors for steroid nuclear receptor-mediated transactivation, as SRC recruits acetyltransferases and methyltransferases that epigenetically modify histones to activate gene expression (8) . Although SRCs do not directly bind to target DNA, SRCs are able to interact with transcription factors, including RORγt, to stimulate transcription (9) . SRCs are thus believed to orchestrate transcription programs critical for multiple functions (8) . However, the in vivo function of SRCs in the immune system remains unexplored.
Protein kinase C theta (PKC-θ) is significantly enriched in T cell compartments (10) and mediates critical costimulatory CD28 signals to regulate T cell activation and differentiation by association with CD28 (10) (11) (12) . PKC-θ-deficient mice are resistant to T cellmediated autoimmunity, including Th17-dependent experimental autoimmune encephalomyelitis (EAE), (13, 14) by inhibiting Th17 and promoting Treg differentiation (15, 16) . However, the molecular mediators of PKC-θ-dependent costimulatory signals in the reciprocal regulation of IL-17
+ and Foxp3 + cell differentiation are not known.
Modulation of RORγt activity by the associated cofactor SRC1 has been noted, but the mechanistic details of how it affects IL-17 transcriptional program and whether it can be controlled by T-cell signaling remained unknown. We demonstrate here that SRC1 is required to establish an unopposed Th17 program by inducing RORγt-SRC1-CARM1 complexes critical for epigenetically opening the IL-17 locus and by overriding Foxp3 inhibition via a PKC-θ-dependent phosphorylation event.
Significance
Poor understanding of the mechanisms responsible for the development of IL-17 + and Foxp3 + cells prevents the development of potent clinical treatments to boost protective Th17 immunity and repress the pathogenic Th17 responses that induce autoimmunity. Here we show that SRC1 phosphorylated by TCR signaling kinase PKC-θ functions as a coactivator in vivo to stimulate RORγt activity by disrupting the binding of inhibitory Foxp3 and induce Foxp3 degradation. SRC1 is thus an important checkpoint downstream of TCR signals to promote the dominance of RORγt over Foxp3 to establish an unopposed Th17 differentiation program. Our results thus provide a rationale for the development of SRC1-based treatments to control the scale of Th17 immunity by reciprocal shift of Th17 and T-regulatory cell differentiation. (Fig. S1H) . SRC1 −/− mice are generally normal, including splenic cellularity (Fig. S2A) , CD4
Results

Deletion
+
/CD8
+ T cell distribution in lymph nodes and spleen (Fig. S2B) , and activationinduced T cell proliferation (Fig. S2C) . Analysis of in vitro T cell differentiation did not detect defects in Th1 and Th2 differentiation of SRC1 −/− CD4 + T cells (Fig. S2 D and E) . However, SRC1
−/− CD4 + T cells developed markedly fewer IL-17 + cells and more Foxp3
+ cells (P < 0.05) ( Fig. 1 A and B) , which was also confirmed using highly purified naive CD4 + T cells (Fig. S2 F and G) . IL-6-mediated activation of Stat3 is critical for Th17 differentiation (17) ; however neither surface expression of the IL-6 receptor or gp130 (Fig. S2H ) nor activation of Stat3 (Fig. S2I ) of SRC1 −/− T cells differed from WT cells. Surface T cell receptor (TCR) and CD28 levels were equivalent on SRC1 −/− and WT T cells (Fig. S2J) 
CD25
+ cells stimulated by αCD3/αCD28 with or without Th17-priming cytokines (Fig. S2K) . We thus focused on understanding SRC1 function in the reciprocal differentiation of IL-17
+ and Foxp3
+ cells under Th17-priming conditions. Deletion of SRC1 did not affect RORγt expression at the protein ( Fig. 1 E and  F) or mRNA level (Fig. S2L) , despite markedly reduced expression of the Th17 signature genes IL-17A, IL-17F, IL-23R, CCL20, and CCR6 (Fig. S2L) . These results denote perturbation of RORγt 
CD4
+ T cells (P < 0.01) ( Fig. 2 B and C) . Reduced production of IL-17A cytokine was observed in restimulated T cells from draining lymph nodes of immunized SRC1 −/− mice (Fig.  S3E) . In contrast, the percentage of Foxp3 + cell accumulation was markedly increased in SRC1 −/− mice compared with WT mice (Fig.  2 D and E) To explore how SRC1 and RORγt coregulate IL-17A transcription, we determined the effects of SRC1 and RORγt on the IL-17A promoter reporter. The expression of SRC1 in the presence of RORγt resulted in significantly increased reporter activity over that induced by RORγt alone, and the action was completely abrogated by a substitution mutation in the SRC1-binding motif of RORγt (RORγt-AF2) ( Fig. S4A ) (9) . Interestingly, SRC1-mediated enhancement of RORγt activity was further amplified in the presence of phorbol 12-myristate 13-acetate (PMA) without a significant effect on RORγt alone (Fig. S4A ).
Since PMA is known to activate PKC, including PKC-θ, we examined whether stimulation with the anti-CD28 antibody, known to couple and activate intracellular PKC-θ (17), could produce a similar effect. Indeed, we found a CD28 dose-dependent increase in SRC1-and RORγt-mediated IL-17A reporter activity ( Together, these results demonstrate that SRC1 promotes IL-17 + but inhibits Foxp3 + cell development in a PKC-θ-dependent manner.
SRC1 Binding and Stimulation of RORγt Are Dependent on PKC-θ
Catalytic Activity. To determine how PKC-θ regulates SRC1-and RORγt-mediated transactivation, we performed a RORγt-luciferase reporter assay in which SRC1-boosted RORγt transcriptional activity was further stimulated by the coexpression of constitutively active PKC-θ (C/A PKC-θ), but not by inactive PKC-θ (I/A PKC-θ), in a dose-dependent manner (Fig. 4A) . Consistently, the SRC1-RORγt physical interaction was enhanced by active, but not inactive, PKC-θ in a dose-dependent manner (Fig.  4B ), demonstrating that PKC-θ kinase activity is required for the SRC1-RORγt interaction. RORγt-AF2 is a mutant that does not bind SRC1, does not stimulate RORγt reporter and thus serves as a negative control. To understand whether RORγt DNA-binding ability is affected in presence of SRC1 and PKC-θ, we used bandshift analysis with an oligonucleotide probe containing the RORγt-binding site from the IL-17A promoter. Coexpression of RORγt and SRC1, having no intrinsic DNA-binding ability, markedly enhanced RORγt DNA-binding activity, as denoted by a higher-intensity RORγt-SRC1-DNA band clearly shifted from the lower-intensity basal RORγt-DNA band (Fig. 4C) . Interestingly, in presence of active PKC-θ, but not inactive PKC-θ, RORγt-SRC1-DNA band intensity increased dose dependently with a simultaneous decrease of the RORγt-DNA band, denoting more pronounced RORγt DNA-binding activity in presence of SRC1 and active PKC-θ. Next, an endogenous RORγt-SRC1 interaction was detected by reciprocal immunoprecipitation with anti-RORγt or anti-SRC1 antibody in differentiated WT Th17 cells (Fig. 4D, Left) ; noticeably more RORγt-SRC1 complexes were detected in the presence of increasing CD28 stimulation, which activates PKC-θ. However, formation of RORγt-SRC1 complexes was minimal in PKC-θ −/− Th17 cells (Fig. 4D, Right) , suggesting the critical function of PKC-θ in inducing the RORγt-SRC1 interaction in vivo. Taken together, our results demonstrate that a catalytically active form of PKC-θ is required to stimulate more pronounced SRC1 and RORγt interaction, which in turn promotes higher DNA-binding activity by RORγt and the subsequent transcriptional functionality.
Serines 1271 and 1272 of SRC1 Are Functional PKC-θ Phosphorylation Sites. Given that catalytically active, but not inactive, PKC-θ stimulates the coactivator properties of SRC1, we detected whether SRC1 was phosphorylated by using an antibody specific for phospho-Ser/Thr in a motif recognized by PKC. Indeed, phosphorylated SRC1 was detected in the presence of active, but not inactive, PKC-θ in a dose-dependent manner (Fig. S5A) . Next, a stretch of seven phosphorylation serines or threonines (Fig. S5B) was identified in cells expressing active, but not inactive, PKC-θ by mass spectrometry. Although individual mutation of other phosphorylation sites to alanine had no effect, S1271A or S1271A significantly impaired the ability of SRC1 to bind and activate RORγt in the presence of active PKC-θ ( Fig. S5 C and D) or to stimulate and rescue the differentiation of IL-17 + cells in WT and SRC1 −/− T cells, respectively ( Fig. S5 E and F) . Multiple sequence alignments showed these two phosphorylation sites to be highly conserved across different species (Fig. S5G) , implying their potentially important function. Since single mutations at S1271 and S1272 only partially impaired SRC1 function, we next made double mutations, either S1271A/S1272A (SRC1 AA ) or phosphomimetic mutations, S1271D/S1272D (SRC1 DD ) and S1271E/S1272E (SRC1 EE ). SRC1 AA failed to stimulate RORγt even in the presence of active PKC-θ, whereas SRC1 DD and SRC1 EE stimulated RORγt independently of active or inactive PKC-θ (Fig. S5H) . As SRC1 EE was equivalent to SRC1 DD , only SRC1 EE was used for the rest of our studies. The overall increase in the structural stability of SRC1 (Fig. S5I) , due to the replacement of serines by glutamic acid, as denoted by the in silico analysis, strongly suggests the importance of the phosphomodifications at S1271 and S1272 in the regulation of SRC1 functionality. Intriguingly, the computational analysis of sequencebased disorder prediction (Fig. S5J ) denotes a higher probability of intrinsic disorder in the particular region of the SRC1 harboring the PKC-θ-targeted S1271A or S1272A residues (amino acids 1,261-1,310). Moreover, the disorder-enhanced phosphorylation site prediction (18) showed a high probability score for phosphorylation of S1271 and S1272 (Fig. S5K) , further supporting the significance of our finding that these two sites are phosphor-modified Statistics are calculated based on three biological replicates. NS, not significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (one-way ANOVA with Tukey's post-analysis multiple-comparison test).
by PKC-θ. In the coimmunoprecipitation study, WT SRC interacted with RORγt in an active PKC-θ dose-dependent manner; SRC1 AA failed to interact with RORγt, even in the presence of active PKC-θ; and SRC1 EE bound to RORγt independent of active or inactive PKC-θ (Fig. 5A) . Band-shift analysis also indicated that active PKC-θ stimulated the formation of RORγt-SRC1-DNA complexes in a dose-dependent manner but failed to stimulate the formation of RORγt-SRC1 AA -DNA complexes, whereas RORγt-SRC1 EE -DNA complexes were formed independently of active or inactive PKC-θ (Fig. 5B) . WT SRC1, but not SRC1 AA , stimulated IL-17 reporter activity in a CD28-stimulation dosedependent manner, whereas SRC1 EE stimulated IL-17 reporter activity independently of CD28 dosage (Fig. S5L) . Therefore, the two identified PKC-θ-targeted phosphorylation sites of SRC1 are essential for stimulating peak RORγt activity by inducing maximal RORγt-SRC1 interaction, subsequent target DNA binding, and RORγt transcriptional ability.
Next, to determine the effect of SRC1 phosphorylation on the IL-17A locus conformation, we monitored histone acetylation [H3K(9)Ac, an active gene marker] at an RORγt-specific site on the IL-17 promoter (Fig. 5C ) and the SRC1-RORγt interaction (Fig. S5M) . SRC1 −/− T cells reconstituted with EV and SRC1 AA had relatively low histone acetylation signals at the IL-17 locus (Fig. 5C , Bottom), which correlated with the lack of interaction between SRC1 AA and RORγt (Fig. S5M) . In contrast, WT SRC1 increased H3K(9)Ac signals and SRC1-RORγt interaction in a CD28 dose-dependent manner, while SRC1 EE increased H3K(9)Ac signals and SRC1-RORγt interaction independent of CD28 dosage. Interestingly, SRC1
AA inhibited H3K(9)Ac signals in WT cells (Fig. 5C , Top) and thus behaved like a dominant negative SRC1. These results thus suggest enhanced IL-17 promoter accessibility marked with permissive histone modifications ensue in presence of phosphorylated SRC1. Finally, SRC1 and SRC1 EE , but not SRC1 AA expressed at the equivalent levels (Fig. S5N) Gene Transcription. The critically important phosphorylation sites (S1271 and S1272) are located within the C-terminal activation domain 2 of SRC1, which is the known CARM1 (coactivator of arginine methyltransferase 1) interaction domain (19) . This led us to speculate whether the phosphomodification of S1271 and S1272 of SRC1 could also affect the recruitment of CARM1, which in turn might affect the accessibility of the IL-17A locus for optimal transcription. Indeed, coexpression of RORγt, SRC1, and CARM1 led to significant increases in RORγt reporter activity compared with that induced by RORγt and SRC1 in presence of active PKC-θ (Fig. S6A) . However, SRC1 AA failed to collaborate with CARM1 to activate the RORγt reporter in the presence of active PKC-θ, while the SRC1 EE synergizes with CARM1 to enhance RORγt in the presence of inactive PKC-θ. CARM1 possesses distinct histone methyltransferase activity to asymmetrically methylate the arginine17 residue of histone3, which is primarily linked to gene activation in vivo (20, 21) . We thus used a catalytic inactive form (E267Q) of CARM1 (22) . In contrast to WT CARM1 (Fig. S6A ), E267Q could not synergize with SRC1 to enhance the RORγt reporter (Fig. 6A) . The significant reduction of the RORγt reporter by E267Q in the presence of SRC1 EE denotes that CARM1 is functionally downstream of SRC1, and its catalytic activity is required for optimal stimulation of RORγt activity.
ChIP with an anti-flag antibody was followed by immunoblotting from WT or SRC1 −/− CD4 + T cells differentiated under Th17 conditions and transduced with flag-tagged constructs of SRC1, SRC1 AA , SRC1 EE , or a C-terminal deletion of the CARM1-binding domain (SRC1-ΔAD2) (Fig. S6B) . The protein complex pulled down along with SRC1 or SRC1 EE had both RORγt and CARM1 along with the distinct presence of H3R17a(me)2. When precipitated from cells transduced with either SRC1 AA or SRC1-ΔAD2, the recovery of RORγt was drastically reduced along with a remarkable loss of CARM1 protein and H3R17a(me)2 (Fig.  S6B) . These results thus point out that CARM1 recruitment and the resultant H3R17a(me)2 modification are critically dependent on the presence of phospho-SRC1. Similarly, the ChIP-qPCR assay detected the enrichment of CARM1 and H3R17a(me)2 at the promoters of the RORγt target genes IL-17A (Fig. 6B ) and IL-23R ( T cells (Fig. S6 D and E) . Collectively, these results demonstrate that phospho-SRC1 plays a dual positive role in promoting the Th17 transcription program by directly up-regulating RORγt activity and recruiting CARM1 to generate permissive H3R17a(me) 2 while concurrently suppressing inhibitory H3K9(me)3 modification, thus rendering an overall active chromatin structure at critical Th17 gene loci.
Phosphorylation of SRC1 Overcomes Foxp3-Mediated Inhibition of
RORγt to Promote Th17 Differentiation. Foxp3 suppressed RORγt-mediated IL-17A promoter activation by a physical interaction (6, 7) . Consistent with previous observations, Foxp3 inhibited RORγt reporter activity, which remained unaltered even in the presence of SRC1 (Fig. S7A) . However, SRC1 together with active, but not inactive, PKC-θ overcame the Foxp3-mediated inhibition and activated the RORγt reporter in a dose-dependent manner. The mutant RORγt-AF2, which cannot bind SRC1, failed to overcome Foxp3 inhibition even in the presence of active PKC-θ and SRC1, indicating that the recruitment of phospho-SRC1 has an essential role in the suppression of Foxp3 inhibition. In the coimmunoprecipitation assay, RORγt predominantly interacted with Foxp3 when both Foxp3 and SRC1 were present (Fig. S7B ). However, with increasing amounts of active, but not inactive, PKC-θ, the RORγt-Foxp3 interaction diminished, and a more prominent RORγt-SRC1 interaction was detected, suggesting that the PKC-θ-induced Statistics are calculated based on three biological replicates. NS, not significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (Student's two-tailed unpaired t test in C; one-way ANOVA with Tukey's post-analysis multiple-comparison test in E) A and B are representatives of three independent experiments.
heightened association of SRC1 with RORγt disrupts the Foxp3-RORγt interaction. Band-shift analysis also showed reduced RORγt-target DNA interaction as a result of increasing amounts of Foxp3 (Fig. S7C) , which explains the inhibition of RORγt activity by Foxp3 (Fig. S7A) . In presence of SRC1, RORγt, and Foxp3, only weak signals of RORγt-SRC1 complexes were detected. However, increasing active, but not inactive, PKC-θ restored the formation of RORγt-SRC1-DNA complexes in a dose-dependent manner, despite the presence of Foxp3, confirming the reversal of Foxp3 inhibition on RORγt DNA-binding activity. Consistently, SRC1
EE , but not SRC1 AA , reverted the Foxp3-mediated inhibition of RORγt activity, as substantiated by luciferase reporter activity (Fig. 7A and Fig. S7D ), coimmunoprecipitation assays of the SRC1-RORγt interaction (Fig. 7B) , and gel-shift assays of SRC1-RORγt-DNA complexes (Fig. 7C) .
Foxp3 binds to RORγt to inhibit the differentiation of IL-17 + cells (6, 7) . Given that phosphorylated SRC1 can overcome the Foxp3-mediated inhibition of RORγt activity by dissociating the Foxp3-RORγt interaction (Fig. 7 A-C) , we tested whether phosphorylation of SRC1 can overcome the Foxp3-inhibited differentiation of IL-17 + cells. For this purpose, both Foxp3 (Thy1.1) and SRC1 (GFP) were retrovirally transduced into CD4 + T cells (Fig. 7  D and E) . Differentiation of IL-17 + cells was not obviously affected in cells negative for both Foxp3 and SRC1 (GFP . Collectively, we demonstrate the mechanisms by which phosphorylated SRC1 overrides the Foxp3-mediated inhibition of RORγt transcriptional activity to maximally induce Th17 differentiation.
To further answer how, despite having unchanged mRNA levels, SRC1 −/− T cells differentiated in vitro under Th17-polarizing conditions accumulate a higher amount of Foxp3 protein than WT Th17 cells (Fig. 1E and Fig. S2L ), we considered the possibility that SRC1 might be involved in the regulation of Foxp3 protein stability. Furthermore, under similar conditions, PKC-θ −/− T cells showed detectably higher levels of Foxp3 + cells, and the level was only reduced by phosphomimetic SRC1 EE but not SRC1 or SRC1 AA , reaffirming the role of PKC-θ-phosphorylated SRC1 in reducing the Foxp3 protein level in differentiating Th17 cells. We monitored Foxp3 levels in the presence and absence of MG132, which inhibits proteasomedependent degradation. Foxp3 was below the detectable level in WT CD4 + T cells differentiated under Th17 conditions (Fig.  8A, Upper) , which is consistent with the observation of fewer Foxp3 + cells under this condition (Fig. 1C ). However, a low level of Foxp3 protein was detected in the presence of MG132, suggesting that blockade of the proteasomal pathway accumulates detectable Foxp3 and implicating the involvement of proteosomal degradation of Foxp3 in Th17 cells. As Foxp3 is susceptible to ubiquitination-induced degradation (23, 24) , we monitored the ubiquitination of Foxp3 (Fig. 8B, Upper) . Tandem ubiquitinbinding entity (TUBE) beads (25) were used to enrich ubiquitinated Data are shown as the mean and SEM of three experiments. NS, not significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (one-way ANOVA with Tukey's post-analysis multiple-comparison test).
proteins. Ubiquitination of Foxp3 was detected in MG132-treated cells with TUBE beads but not with control beads. In contrast to WT cells, Foxp3 was detectably higher in SRC1 or GFP together with the indicated SRC1 and retrovirus expressing Thy1.1 alone or together with Foxp3 and differentiated under Th17-priming conditions. (E) Quantification of the results shown in D. NS, not significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (Student's two-tailed unpaired t test; oneway ANOVA-with Tukey's post-analysis multiple-comparison test in E). B and C are representatives of three independent experiments.
Discussion
Our results demonstrate multiple events occurring either concurrently or sequentially during the Th17 developmental pathway: (i) Phosphorylation induced higher interaction of phospho-SRC1 + differentiation. We demonstrate here that the CD28 signaling molecule PKC-θ is the downstream sensor that coordinates RORγt and Foxp3 activity via phosphorylation of coactivator SRC1. In response to CD28 costimulation, PKC-θ mediates the phosphorylation of two conserved serines (1271 and 1272) in SRC1. Notably, the overall increase in the structural stability of SRC1 due to phosphomodification of the two serines and the higher probability score for phosphorylation of S1271 and S1272, as denoted by the computational analysis and further verified by empirical lossand gain-of-function studies, collectively signify the physiological importance of these phosphomodifications in the regulation of SRC1 functionality in the T cell context. Both RORγt and Foxp3 expression can be induced in the same T cells, and RORγt
+
Foxp3
+ double-positive cells are detected in vivo (6, 7, 28) . The final fate of these double-positive cells is controlled by the balance between RORγt and Foxp3 activity. SRC1 exerts dual actions on these two opposing transcription factors to leverage the action of one over the other. Our results indeed demonstrate that PKC-θ-mediated phosphomodification of SRC1 eventuates the release of bound Foxp3 from RORγt, either due to conformational change or steric constraints or through competitive binding. The displaced Foxp3 is subsequently degraded via the ubiquitination pathway, resulting in uninhibited stimulation of IL-17
+ differentiation with reciprocal attenuation of Foxp3-mediated differentiation. We show that Foxp3 is degraded via a previously known (23) STUB1-dependent ubiquitination and proteosomal pathway. As evidenced before (23) , the absence of Stub1 in differentiated T cells under Th17-skewing culture conditions increased Foxp3 expression relative to controls. This implies that in normally differentiating Th17 cells the accumulation of Foxp3 is prevented by prompt proteosomal degradation mediated by Stub1. Our study thus provides the mechanistic basis for how Foxp3 is dissociated and/or simultaneously prevented from association with RORγt and hence is directed to Stub1-mediated proteosomal degradation. Besides, it has also been shown that inflammatory cytokines such as IL1β promote Foxp3 degradation via the Stub1-dependent pathway (23) . Therefore, it is possible that IL1β, being present in the micromilieu of developing Th17 cells in vivo, might provide the degradation signal by acting through IL-1R, a direct target of RORγt. It is possible that phosphorylated SRC1 promotes IL-1β-induced Foxp3 degradation by stimulating RORγt-dependent IL-1R expression; this could be an interesting topic for future investigation.
Multiple transcription factors have been shown to regulate the development of IL-17 + and Foxp3 + cells (29) . While we could not find any change in the binding pattern of IRF4, BATF, or RUNX1 to RORγt complexes in the absence of SRC1 (Fig. S7H) , further analysis of SRC1-interacting transcription factors and their target genes will facilitate a better understanding of how SRC1 orchestrates these transcription factors to regulate reciprocal Th17 and Treg differentiation at a genome-wide level. SRC1 inhibitors have been developed to treat cancer (8, 30) . SRC1 inhibitors are expected to relieve Th17-mediated autoimmunity by both decreasing Th17 and increasing Treg cells simultaneously. Therefore, our study provides the rationale for the development of SRC1-based treatments.
Experimental Procedures
Mice. All animal experiments were performed in specific pathogen-free facilities in the Beckman Research Institute, City of Hope following national, state, and institutional guidelines. Animal protocols were approved by the 
